Galen Partners gets funding from Siemens VC

STAMFORD, CT "� July 16, 2007 "� Galen Partners, a leading private equity firm focusing on the healthcare industry, today announced that Siemens Venture Capital GmbH has invested in its fifth fund, Galen Partners V, L.P. The fund closed in June 2007 with $250 million in total limited partner commitments. Consistent with its earlier funds, Galen Partners V will focus on investments in healthcare information technology/outsourcing, medical devices and specialty pharmaceutical companies.

Galen Partners V, L.P. provides expansion capital to healthcare related companies with established revenue that have the potential for rapid growth and market leadership. The partnership seeks opportunities to actively participate as a lead investor in which it can provide between $10 million and $30 million of equity capital.

"With their long standing experience as a healthcare investor, Galen is best positioned to capitalize on promising venture investment opportunities in the healthcare sector. Our investment in the recently raised Galen Partners V Fund further cements our strategic partnership with Galen," said Doris Blasel, Managing Partner Fund-of-Fund at Siemens Venture Capital. "This cooperation is a critical piece of our corporate venture strategy that helps us to identify potential investment and business opportunities in the U.S. healthcare sector early-on. In addition, Galen's healthcare network provides an ideal complement to our internal Siemens Medtech and business know-how."

Galen Partners V will be managed by a team of eight investment professionals. Members include managing directors David Jahns, Zubeen Shroff, Toby Wesson and John Wilkerson, as well as David Azad, Stacey Bauer, Andrew Isaacson and Michael Koby.

"We are very pleased to again welcome Siemens Venture Capital to our family of limited partners," said David W. Jahns, General Partner at Galen Partners. "We deeply value the strong relationships that we enjoy with our investors and look forward to continuing our productive strategic relationship with Siemens."

The firm has made investments in over 60 companies since 1990 and continues a tradition of strategic collaboration and partnership with its portfolio company management teams. In its most recent fund, Galen was the lead or co-lead investor and served on the board of directors in 100% of its investments. Galen's capital and guidance has helped to build many healthcare market leaders including EduNeering, Encore Medical, Lumenos, MedAssets, Medicode, MiniMed, Ocular Sciences and Pyxis. With the new fund, Galen Partners has nearly $1 billion under management.

About Galen Partners

Galen Partners is a leading healthcare private equity firm based in Stamford, CT. The firm focuses on equity investments in healthcare information technology/outsourcing, medical devices and specialty pharmaceutical companies. With nearly $1 billion under management raised through five funds, Galen has invested in more than 60 companies since 1990. The partnership seeks opportunities to actively participate as a lead investor in which it can provide between $10 million to $30 million of equity capital in healthcare related companies with established revenue. The firm continues a tradition of strategic collaboration and partnership with its portfolio company management teams. Galen's capital and guidance has helped to build many healthcare market leaders including EduNeering, Encore Medical, Lumenos, MedAssets, Medicode, MiniMed, Ocular Sciences and Pyxis. For more information, please visit Galen's website at www.galen.com.

About Siemens Venture Capital

Siemens Venture Capital (SVC) is the corporate venture organization for Siemens AG, one of the largest global electronics and engineering companies, with reported worldwide sales of 87.3 billion euros in fiscal 2006. SVC's goal is to identify and fund investments in emerging and innovative technologies that will enhance the core business scope of Siemens, particularly in the focus areas of long-term growth markets such as Energy & Environmental Care, Automation & Control, Industrial & Public Infrastructure, and Health Care.

To date, SVC has invested over 700 million euros in more than 100 startup companies and 35 venture capital funds, making venture capital at Siemens an integral component of the Siemens innovation and growth strategy and supplementing its in-house research and development activities (5.7 billion euros and 50,000 R&D experts in 2006).

SVC is located in Germany (Munich), in the U.S. (San José, CA and Boston, MA), in China (Beijing), in India (Mumbai), and is active through Siemens´ regional unit in Israel. www.siemensventurecapital.com